Major responses have been demonstrated in various B‐cell malignancies (Bargou et al, 2008; Topp et al, 2011), and BiTEs have been designed targeting different tumour‐associated antigens including EpCAM, Her2/neu, EGFR, CEA, EphA2, CD33 and MCSP with some currently under clinical evaluation (Baeuerle & Reinhardt, 2009; Yuraszeck et al, 2017). This evidence concerns the gene ERBB2 and neoplasm.